Bioactivation of tamoxifen by recombinant human cytochrome p450 enzymes.
Tamoxifen is a major drug used for adjuvant chemotherapy of breast cancer; however, its use has been associated with a small but significant increase in risk of endometrial cancer. In rats, tamoxifen is a hepatocarcinogen, and DNA adducts have been observed in both rat and human tissues. Tamoxifen has been shown previously to be metabolized to reactive products that have the potential to form protein and DNA adducts. Previous studies have suggested a role for P450 3A4 in protein adduct formation in human liver microsomes, via a catechol intermediate; however, no clear correlation was seen between P450 3A4 content of human liver microsomes and adduct formation. In the present study, we investigated the P450 forms responsible for covalent drug-protein adduct formation and the possibility that covalent adduct formation might occur via alternative pathways to catechol formation. Recombinant P450 3A4 catalyzed adduct formation, and this correlated with the level of uncoupling in the P450 incubation, consistent with a role of reactive oxygen species in potentiating adduct formation after enzymatic formation of the catechol metabolite. Whereas P450s 1A1, 2D6, and 3A5 generated catechol metabolite, no covalent adduct formation was observed with these forms. By contrast, P450 2B6, 2C19, and rat liver microsomes catalyzed drug-protein adduct formation but not catechol formation. Drug protein adducts formed specifically with P450 3A4 in incubations using membranes isolated from bacteria expressing P450 3A4 and reductase, as well as in reconstitutions of purified 3A4, suggesting that the electrophilic species reacted preferentially with the P450 enzymes concerned.
Notley
Lisa M
LM
Department of Physiology and Pharmacology, School of Biomedical Sciences, University of Queensland, St.Lucia, Australia 4072.
De Wolf
Cornelia J F
CJ
Wunsch
Rebecca M
RM
Lancaster
Roy G
RG
Gillam
Elizabeth M J
EM
D000818:Animals; D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000378:metabolism*; D002396:Catechols / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism* / Q000502:physiology; D018736:DNA Adducts / Q000096:biosynthesis; D006801:Humans; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013629:Tamoxifen / Q000009:adverse effects / Q000378:metabolism*
D016588:Anticarcinogenic Agents; D002396:Catechols; D018736:DNA Adducts; D013629:Tamoxifen; D003577:Cytochrome P-450 Enzyme System; C034221:catechol